FOUNTAIN VALLEY, Calif., June 6, 2016 /PRNewswire-iReach/ -- Prussian blue is an electroactive dye that uniquely incorporates monocations belonging to the alkali metal group, such as K+ and Na+, and is used as a sequestering agent for thallium (TI) and cesium (Cs). With the use of Prussian blue screen-printed electrodes and electrochemical characterization methods, we are reporting here the differential detection of K+ and Na+ in phosphate buffered saline (PBS) and fetal bovine serum (FBS), mimicking physiological conditions. The concentration differences between potassium (K) and sodium (Na) ions in the human body generate the membrane potential needed for normal cellular functions, including muscle function. Thus, it is important to be able to monitor extracellular K+ concentrations in human fluids, especially prior to or during cardiac surgery.
Logo - http://photos.prnewswire.com/prnh/20160602/375071LOGO
The Prussian blue screen-printed electrode exhibits distinct square-wave voltammetry scans when exposed to alkali cations including Na+ or K+, while bivalent cations (Ca2+, Mg2+) or smaller alkali metals (Li+) did not affect the measurements. The increasing presence of K+ in physiological buffer, which contains primarily Na+, resulted in a concentration dependent shift in the square-wave voltammetry scan. This property can be used to quantify both Na+ and K+ concentrations in physiological fluid and, in turn, the membrane potential. As Prussian blue is nontoxic in vivo, the biosensor offers the potential to be implanted for the continuous monitoring of K+ and Na+. Furthermore, the Prussian blue screen-printed electrode requires a small volume of sample, which is advantageous in the biomedical field if patient blood or serum is to be tested. The application of Prussian blue to monitor other monocations, especially the therapeutically important monocations (TI and Cs), is being investigated.
The poster presentation will be held at the 16th International Conference on Electroanalysis (ESEAC 2016) in Bath, United Kingdom.
Title: | Prussian Blue Screen-Printed Electrode as Specific Biosensor for K+ |
Location: | The Assembly Rooms, Bath, UK |
Date and Time: | Wednesday June 15 2016, 11:10am - 11:30am in Tea Room |
Authors: | Samuel Dixon, William Yeh, Dongwon Lee, Shradha Prabhulkar, Cynthia Lee, Vuong Trieu |
Institution: | Autotelic Inc. Fountain Valley, CA 92708 |
About Autotelic Inc.
Autotelic works through our partners to transform how medications are being delivered. The Autotelic Inc. platform is our Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. Current dosing schemes result in either too much drug exposure or too little drug exposure because of individual pharmacokinetic variations. Autotelic’s pipeline includes TDM devices for management of oncology, hypertension and pain. More information is available at www.autotelicinc.com.
About ESEAC
The International Conference on Electroanalysis (ESEAC) brings together research scientists from around the world to discuss recent discoveries and further the field that is electroanalytical chemistry. ESEAC will combine scientific excellence with culture and history of the region. The conference includes poster presentations, oral presentations, and keynote speakers addressing a wide range of electroanalysis topics, from theoretical approaches to practical applications. Scientists will discuss their findings in an academic setting and seek out information to better their personal projects. Through discussion with world-renown scholars, scientists will gain a greater understanding of electroanalytical chemistry. More information is available at www.eseac2016.com.
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. We caution you that any forward-looking information provided by or on our behalf is not a guarantee of future performance. Forward-looking statements include: (I) changes in domestic and foreign economic or non-economic conditions, (II) the effect of federal, state and foreign FDA regulations, (III) Intellectual property and other claims, (IV) the effect of our clinical and non-clinical trial, (V) the impact on our branding strategy and other factors. All such forward-looking statements are current only as of the date on which such statements are made. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of the companies may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. The companies above neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
Media Contact: Vuong Trieu PhD., Autotelic Inc., 8185759505, info@autotelicinc.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Autotelic Inc.
